Pfizer COVID-19 vaccine effectiveness drops 6 months after 2nd dose: study – National

The effectiveness of the Pfizer Inc/BioNTech SE vaccine in stopping an infection by the coronavirus dropped to 47% from 88% six months after the second dose, based on information revealed on Monday that U.S. well being businesses thought of when deciding on the necessity for booster photographs.

The info, which was revealed within the Lancet medical journal, had been beforehand launched in August forward of peer evaluate.

Learn extra:
Pfizer launches large study of oral COVID-19 prevention drug

The evaluation confirmed that the vaccine’s effectiveness in stopping hospitalization and dying remained excessive at 90% for a minimum of six months, even in opposition to the extremely contagious Delta variant of the coronavirus.

The info means that the drop is because of waning efficacy, reasonably than extra contagious variants, researchers mentioned.

Story continues under commercial

Researchers from Pfizer and Kaiser Permanente studied digital well being information of roughly 3.4 million individuals who had been members of Kaiser Permanente Southern California between December 2020 – when the vaccine first grew to become out there – and August of 2021.

“Our variant-specific evaluation clearly exhibits that the (Pfizer/BioNTech) vaccine is efficient in opposition to all present variants of concern, together with Delta,” mentioned Luis Jodar, senior vice chairman and chief medical officer at Pfizer vaccines.

Click to play video:'Why your flu shot could be even more important this year'

Why your flu shot may very well be much more necessary this yr

Why your flu shot may very well be much more necessary this yr

A possible limitation of the examine was a scarcity of information on adherence to masking tips and occupations within the examine inhabitants, which might have affected frequency of testing and probability of publicity to the virus.

Vaccine effectiveness in opposition to the Delta variant was 93% after the primary month, declining to 53% after 4 months. Towards different coronavirus variants, efficacy declined to 67% from 97%.

Story continues under commercial

Learn extra:
The booster debate: Will you need a third COVID-19 shot?

“To us, that implies Delta just isn’t an escape variant that’s utterly evading vaccine safety,” mentioned examine chief Sara Tartof with Kaiser Permanente Southern California’s Division of Analysis & Analysis.

“If it was, we’d most likely not have seen excessive safety after vaccination, as a result of vaccination wouldn’t be working in that case. It will begin low, and keep low.”

Testing for variants is extra more likely to fail in vaccinated people, which might result in overestimation of variant-specific effectiveness within the examine, the authors cautioned.

The U.S. Meals and Drug Administration has licensed using a booster dose of the Pfizer/BioNTech vaccine for older adults and a few Individuals at high-risk of getting contaminated. Scientists have referred to as for extra information on whether or not boosters needs to be really useful for all.

Click to play video:'Should we be concerned about ‘waning immunity’?'

Ought to we be involved about ‘waning immunity’?

Ought to we be involved about ‘waning immunity’? – Sep 25, 2021

(Reporting by Manas Mishra in Bengaluru; Enhancing by Invoice Berkrot) | Pfizer COVID-19 vaccine effectiveness drops 6 months after 2nd dose: examine – Nationwide


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button